1 unchanged sentence
During the three months ended
−Removed: June 30, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule
−Removed: 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
+Added: September 30, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement
+Added: or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
EXHIBIT INDEX
9 unchanged sentences
January 25, 2023
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp.
+Added: Current Report on Form 8-K (File No.
Amended and Restated Bylaws of Phio Pharmaceuticals Corp.
Current Report on Form 8-K (File No.
−Removed: Purchase Agreement, dated May 16, 2024, by and between Phio Pharmaceuticals Corp.
−Removed: and Triton Funds LP.
+Added: Form of Series C/D Warrant, dated July 12, 2024.
Current Report on Form 8-K (File No.
−Removed: 2020 Phio Pharmaceuticals Corp.
−Removed: Long Term Incentive Plan, as amended and restated.
+Added: July 12, 2024
+Added: Form of Placement Agent Warrant, dated July 12, 2024.
Current Report on Form 8-K (File No.
−Removed: June 21, 2024
−Removed: Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer.
+Added: July 12, 2024
+Added: Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp.
+Added: and the Holders.
+Added: Current Report on Form 8-K (File No.
+Added: July 12, 2024
+Added: Offer Letter, executed July 16, 2024, by and between the Company and Robert M.
+Added: Current Report on Form 8-K (File No.
+Added: August 1, 2024
+Added: Sarbanes-Oxley Act Section 302 Certification of Principal Executive
Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer.
11 unchanged sentences
Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.
−Removed: Pursuant to the requirements of the Securities
−Removed: Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: Pursuant to the requirements
+Added: of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
+Added: duly authorized.
Phio Pharmaceuticals Corp.
2 unchanged sentences
(as Principal Executive Officer)
−Removed: August 14, 2024
+Added: November 14, 2024
/s/ Robert M.
1 unchanged sentence
(as Principal Financial Officer)
−Removed: August 14, 2024
+Added: November 14, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.